Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1183 | 1050 | 1217 | 1224 | 1560 | 2685 |
Fund Return | 18.26% | 5.04% | 21.72% | 6.97% | 9.3% | 10.38% |
Place in category | 1330 | 1268 | 1276 | 913 | 711 | 148 |
% in Category | 76 | 71 | 74 | 61 | 59 | 27 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Renaissance Global Growth Cl F CAD | 4.82B | 19.66 | 8.36 | 11.83 | ||
Renaissance International Eq CAD | 1.81B | 5.69 | 0.41 | 6.70 | ||
Renaissance International Eq Cl CAD | 1.81B | 6.94 | 1.70 | 8.14 | ||
Renaissance US Equity Income F CAD | 1.46B | 24.11 | 11.18 | 10.78 | ||
Renaissance US Eq Income F Pr CAD | 1.46B | 24.17 | 11.24 | 10.91 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity Global Innovators Class F | 16.18B | 55.54 | 14.87 | - | ||
Mawer Global Equity | 13.85B | 11.93 | 6.20 | 10.88 | ||
Capital Group Glbal Equity Fd F CAD | 13.95B | 27.39 | 5.28 | 11.77 | ||
Capital Group Glbal Equity Fd A CAD | 13.95B | 26.11 | 4.12 | 10.53 | ||
Capital Group Glbal Equity Fd D CAD | 13.95B | 27.03 | 4.93 | 11.29 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 4.04 | 648.5 | +10.06% | |
Microsoft | US5949181045 | 3.68 | 436.60 | -0.10% | |
Taiwan Semiconductor | US8740391003 | 3.68 | 197.21 | +1.32% | |
Amphenol | US0320951017 | 3.28 | 70.58 | +0.81% | |
Linde PLC | IE000S9YS762 | 2.89 | 407.000 | +0.25% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Buy | Buy |
Technical Indicators | Sell | Strong Buy | Strong Buy |
Summary | Sell | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review